Cencora (COR) Stock Overview
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
COR Community Fair Values
Create NarrativeSee what 33 others think this stock is worth. Follow their fair value or set your own to get alerts.
Cencora, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$311.77 |
| 52 Week High | US$315.23 |
| 52 Week Low | US$218.65 |
| Beta | 0.62 |
| 1 Month Change | 6.91% |
| 3 Month Change | 5.25% |
| 1 Year Change | 40.67% |
| 3 Year Change | 118.86% |
| 5 Year Change | 226.15% |
| Change since IPO | 10,457.29% |
Recent News & Updates
Recent updates
Cencora, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 09
Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy
Aug 08Why We're Not Concerned About Cencora, Inc.'s (NYSE:COR) Share Price
Apr 07Cencora: Great Track Record And Outlook, But Valuation Does Not Offer Upside
Feb 25Is Cencora (NYSE:COR) Using Too Much Debt?
Jan 27Cencora's (NYSE:COR) Soft Earnings Are Actually Better Than They Appear
Dec 05Cencora (NYSE:COR) Is Increasing Its Dividend To $0.55
Nov 09Why We're Not Concerned About Cencora, Inc.'s (NYSE:COR) Share Price
Oct 31Here's Why We Think Cencora (NYSE:COR) Is Well Worth Watching
Oct 10Cencora: Credentials To Die For, But Underlying Issues Make Case For 'Hold' Rating
Sep 18Cencora: Potential Exists, But Ambiguous Valuations And Data Breach Risks Are Concerning
Jun 30Cencora Remains Chronically Undervalued, With Material Growth Potential
Mar 25Cencora: Continued Economic Value On The Table Across All Investment Horizons
Jan 04Shareholder Returns
| COR | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 1.1% | -0.2% | 0.8% |
| 1Y | 40.7% | -21.8% | 18.1% |
Return vs Industry: COR exceeded the US Healthcare industry which returned -22.3% over the past year.
Return vs Market: COR exceeded the US Market which returned 18% over the past year.
Price Volatility
| COR volatility | |
|---|---|
| COR Average Weekly Movement | 3.5% |
| Healthcare Industry Average Movement | 6.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: COR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: COR's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1871 | 44,000 | Bob Mauch | www.cencora.com |
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Cencora, Inc. Fundamentals Summary
| COR fundamental statistics | |
|---|---|
| Market cap | US$60.59b |
| Earnings (TTM) | US$1.90b |
| Revenue (TTM) | US$316.65b |
Is COR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COR income statement (TTM) | |
|---|---|
| Revenue | US$316.65b |
| Cost of Revenue | US$305.88b |
| Gross Profit | US$10.77b |
| Other Expenses | US$8.87b |
| Earnings | US$1.90b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 9.79 |
| Gross Margin | 3.40% |
| Net Profit Margin | 0.60% |
| Debt/Equity Ratio | 372.9% |
How did COR perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/01 13:50 |
| End of Day Share Price | 2025/10/01 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cencora, Inc. is covered by 39 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Gregory Bolan | Avondale Partners |
| Eric Coldwell | Baird |